- Home
- PFL vs SIGA Comparison
PFL vs SIGA Comparison
Compare PFL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.22
Company Overview
Basic Information| Metric | PFL | SIGA |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.7M | 401.0M |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PFL | SIGA |
|---|---|---|
| Price | $7.99 | $5.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 276.9K | ★ 817.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.53% | 11.45% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | ★ N/A | $16.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.11 | $4.81 |
| 52 Week High | $8.70 | $9.62 |
Technical Indicators
Market Signals| Indicator | PFL | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 42.36 |
| Support Level | N/A | $4.81 |
| Resistance Level | $8.49 | $6.98 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 67.31 | 63.61 |
Price Performance
Historical Comparison PFL
SIGA
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.